Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects

ClinicalTrials.gov ID: NCT01210352

Public ClinicalTrials.gov record NCT01210352. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 24, 2026, 12:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label, Non-randomized, Multicenter, Ascending Dose by Age, Single- and Multiple-Dose Evaluation of the Effectiveness, Safety, and Tolerability of Oral Liquid Oxymorphone HCl Immediate-Release Oral Liquid for Acute Postoperative Pain in Pediatric Subjects

Study identification

NCT ID
NCT01210352
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Enrollment
61 participants

Conditions and interventions

Interventions

  • oxymorphone HCl Drug

Drug

Eligibility (public fields only)

Age range
0 Years to 12 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 12, 2010
Primary completion
Oct 5, 2017
Completion
Oct 5, 2017
Last update posted
Aug 19, 2021

2010 – 2017

United States locations

U.S. sites
8
U.S. states
8
U.S. cities
8
Facility City State ZIP Site status
Endo Clinical Trial Site #19 Tucson Arizona 85724
Endo Clinical Trial Site #1 Little Rock Arkansas 72202
Endo Clinical Trial Site #3 Aurora Colorado 80045
Endo Clinical Trial Site #6 Indianapolis Indiana 46202
Endo Clinical Trial Site #11 Oklahoma City Oklahoma 73104
Endo Clinical Trial Site #12 Pittsburgh Pennsylvania 15224
Endo Clinical Trial Site #13 Nashville Tennessee 37232
Endo Clinical Trial Site #14 Dallas Texas 75235

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01210352, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 19, 2021 · Synced Jul 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01210352 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →